Premier Energies Declares Second Interim Dividend of ₹0.75 P...
Source: scanx.trade
Shringar House of Mangalsutra Limited has filed its Monitoring Agency Report for the quarter ended March 31, 2026, with the National Stock Exchange of India Limited and BSE Limited, pursuant to Regulation 32 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The report was prepared by Crisil Ratings Limited in its capacity as the designated Monitoring Agency, under the Monitoring Agency Agreement dated August 22, 2025, and in accordance with Schedule XI of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The Audit Committee reviewed the report at its meeting held on May 06, 2026, and the submission was signed by Rachit S Sinha, Company Secretary and Compliance Officer.
IPO Issue Details
The company conducted its Initial Public Offer during the period from September 09, 2025 to September 12, 2025, comprising a fresh issuance of equity shares. The gross proceeds from the IPO stood at Rs. 4,009.20 million, which Crisil Ratings monitors in its entirety. The net proceeds, after accounting for issue expenses, were revised during the quarter ended December 31, 2025, from Rs. 3,588.79 million to Rs. 3,613.57 million. This revision arose because the actual utilisation of proceeds towards issue expenses was lower than the estimated expenses disclosed in the offer document, resulting in a surplus of Rs. 24.78 million, which was added to the General Corporate Purposes allocation.
The following table summarises the issue size and expense breakdown:
Particulars: Amount (Rs. million) Gross Proceeds of the Fresh Issue: 4,009.20 Less: Issue Expenses: 395.63 Net Proceeds: 3,613.57
Object-wise Cost and Utilisation
The IPO proceeds were earmarked for two primary objects — funding working capital requirements and general corporate purposes — in addition to issue expenses. The revised cost allocation, following the adjustment noted above, is presented below:
Sr. No.: Item Head: Original Cost (Rs. million): Revised Cost (Rs. million): 1: Funding Working Capital Requirements: 2,800.00 2,800.00 2: General Corporate Purposes: 788.79 813.57 Sub-total: 3,588.79 3,613.57 3: Issue Expenses: 420.41 395.63 Total: 4,009.20 4,009.20
As at the end of the quarter ended March 31, 2026, the progress in utilisation of proceeds across all objects is detailed below:
Item Head: Revised Amount (Rs. million): Amount Utilised at Beginning of Quarter (Rs. million): Amount Utilised During Quarter (Rs. million): Amount Utilised at End of Quarter (Rs. million): Total Unutilised (Rs. million): Funding Working Capital Requirements: 2,800.00 2,800.00 Nil 2,800.00 Nil General Corporate Purposes: 813.57 813.57 Nil 813.57 Nil Sub-total: 3,613.57 3,613.57 Nil 3,613.57 Nil Issue Expenses: 395.63 385.52 3.02 388.54 7.09 Total: 4,009.20 3,999.09 3.02 4,002.11 7.09
Proceeds allocated towards funding working capital requirements and general corporate purposes were fully utilised as of the quarter ended December 31, 2025. During the quarter ended March 31, 2026, the company utilised Rs. 3.02 million from its cash credit account maintained with Kotak Bank towards issue expenses, for operational ease. The amount utilised for general corporate purposes did not exceed 25% of the gross proceeds, which equates to Rs. 1,002.25 million from the fresh issue.
Deployment of Unutilised Proceeds
As at the quarter ended March 31, 2026, the remaining unutilised balance of Rs. 7.09 million was held in the company's Public Offer Account maintained with Axis Bank (Account No. 925020037457981). The company confirmed that none of the unutilised funds have been encumbered as lien for any purpose.
Sr. No.: Instrument / Entity: Amount Invested (Rs. million): Market Value as at March 31, 2026 (Rs. million): 1: Balance in Public Offer Account — Axis Bank (925020037457981): 7.09 07.09 Total: 7.09
Monitoring Agency Findings
Crisil Ratings confirmed that all utilisation of IPO proceeds is in accordance with the objects disclosed in the offer document, covering funding of working capital requirements, general corporate purposes, and issue expenses. The monitoring agency reported no deviation from the objects of the issue, no change in the means of finance, and no major deviation observed over earlier monitoring agency reports. All government and statutory approvals related to the objects have been obtained. No unfavourable events affecting the viability of the objects were noted, and no other material information affecting investor decision-making was identified.
The report was prepared on the basis of a management undertaking and a peer-reviewed Independent Chartered Accountant Certificate dated April 16, 2026, issued by M/s J F Jain & Co, Chartered Accountants (Firm Registration Number: 112599W). There is no delay in utilisation towards the objects of the issue, as confirmed by the Chartered Accountant's certificate. The report was signed by Shounak Chakravarty, Director, Ratings (LCG), Crisil Ratings Limited, and submitted on May 06, 2026.
Shringar House of Mangalsutra Limited has announced an upcoming plant visit interaction with investors and analysts, scheduled for May 4-5, 2026. The company informed both NSE and BSE about this event on April 24, 2026, in compliance with regulatory requirements.
Event Details
The investor interaction is organized as per the following schedule:
Parameter: Details Event Type: Plant Visit (Group of Investors) Date: May 4-5, 2026 (Monday & Tuesday) Location: Kandivali, Mumbai Mode: In person NSE Symbol: SHRINGARMS BSE Scrip Code: 544512
Regulatory Compliance
The announcement was made pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para A of Part A of Schedule III of the said Regulations. Company Secretary and Compliance Officer Rachit S Sinha signed the notification on April 24, 2026, ensuring proper adherence to disclosure norms.
Discussion Framework
The company has clarified that discussions during the plant visit will be based exclusively on publicly available information. No unpublished price-sensitive information is intended to be discussed during the visit, maintaining transparency and regulatory compliance.
Operational Flexibility
Shringar House of Mangalsutra Limited has noted that the meeting schedule may undergo changes due to exigencies on the part of participants or the company. This provision allows for necessary adjustments while maintaining the commitment to investor engagement.
Company Information
The company operates from its registered office at Unit No. B-1, Lower Ground Floor, Jewel World (Cotton Exchange Building), Kalbadevi Road, Mumbai. The manufacturing facility is located at Ground, 1st & Part of 2nd Floor, Gala No. 21 ABCD, Government Industrial Estate, Charkop, Kandivali West, Mumbai. The plant visit will provide investors with firsthand insights into the company's manufacturing operations and business processes.
We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.
Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.
Disclaimer:
The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.
Source: scanx.trade